Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Update on Biomarkers in Spinal Muscular Atrophy
Megan G. Pino, Kelly Rich, Stephen J. Kolb
Biomarker Insights (2021) Vol. 16
Open Access | Times Cited: 44

Showing 1-25 of 44 citing articles:

Curing SMA: Are we there yet?
Aoife Reilly, Lucia Chehadé, Rashmi Kothary
Gene Therapy (2022) Vol. 30, Iss. 1-2, pp. 8-17
Open Access | Times Cited: 43
Spinal Muscular Atrophy: An Evolving Scenario through New Perspectives in Diagnosis and Advances in Therapies
Ilaria Angilletta, Rossella Ferrante, Roberta Giansante, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14873-14873
Open Access | Times Cited: 25
Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges
Sherif Bayoumy, Inge M.W. Verberk, Lisa Vermunt, et al.
Clinical Chemistry and Laboratory Medicine (CCLM) (2024) Vol. 62, Iss. 7, pp. 1252-1265
Open Access | Times Cited: 16
The impact of three SMN2 gene copies on clinical characteristics and effect of disease-modifying treatment in patients with spinal muscular atrophy: a systematic literature review
Claudia Dosi, Riccardo Masson
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 9
Molecular Biomarkers of Neurodegenerative Disorders: A Practical Guide to Their Appropriate Use and Interpretation in Clinical Practice
Luisa Agnello, Caterina Maria Gambino, Anna Maria Ciaccio, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 8, pp. 4323-4323
Open Access | Times Cited: 9
Identification of Novel Biomarkers of Spinal Muscular Atrophy and Therapeutic Response by Proteomic and Metabolomic Profiling of Human Biological Fluid Samples
Megi Meneri, Elena Abati, Delia Gagliardi, et al.
Biomedicines (2023) Vol. 11, Iss. 5, pp. 1254-1254
Open Access | Times Cited: 17
Biomarkers in 5q-associated spinal muscular atrophy—a narrative review
Hilmar Lapp, Maren Freigang, Tim Hagenacker, et al.
Journal of Neurology (2023) Vol. 270, Iss. 9, pp. 4157-4178
Open Access | Times Cited: 16
Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
Jacqueline Glascock, Basil T. Darras, Thomas O. Crawford, et al.
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 5, pp. 937-954
Open Access | Times Cited: 16
Molecular Biomarkers for the Diagnosis, Prognosis, and Pharmacodynamics of Spinal Muscular Atrophy
Marija Babić, Maria Banović, Ivana Berečić, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 15, pp. 5060-5060
Open Access | Times Cited: 13
Spinal cord gray matter atrophy is associated with disability in spinal muscular atrophy
Eva Kesenheimer, Maria Janina Wendebourg, Claudia Weidensteiner, et al.
Journal of Neurology (2025) Vol. 272, Iss. 1
Open Access
Motor function and compound muscle action potential amplitude in children with spinal muscular atrophy treated with nusinersen
Yu Peng, Lianying Feng, Jinfeng Wu, et al.
Brain and Development (2025) Vol. 47, Iss. 1, pp. 104316-104316
Closed Access
Identifying novel response markers for spinal muscular atrophy revealed by targeted proteomics following gene therapy
Devesh C. Pant, Sumit Verma
Gene Therapy (2025)
Closed Access
Sustainable Mealworm Tofu as a Dietary Strategy to Prevent Muscle Atrophy Induced by Dexamethasone in Cellular and Animal Models
Eunyoung Oh, Min Hee Kim, Woo‐Jae Park, et al.
Food Hydrocolloids for Health (2025), pp. 100211-100211
Open Access
Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
Francesco Errico, Carmen Marino, Manuela Grimaldi, et al.
Biomolecules (2022) Vol. 12, Iss. 10, pp. 1431-1431
Open Access | Times Cited: 15
Evaluation of risdiplam efficacy in 5q spinal muscular atrophy: A systematic comparison of electrophysiologic with clinical outcome measures
Tobias Keßler, Georges Sam, Wolfgang Wick, et al.
European Journal of Neurology (2023) Vol. 31, Iss. 1
Open Access | Times Cited: 9
Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective
Lakshmi Balaji, Michelle A. Farrar, Arlene D’Silva, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 7, pp. 571-586
Closed Access | Times Cited: 8
Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era
Giorgia Querin, M. Gómez García de la Banda, Piera Smeriglio
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 8
NAIP Gene Deletion and SMN2 Copy Number as Molecular Tools in Predicting the Severity of Spinal Muscular Atrophy
Abdel Nasser H Abd El Mutaleb, Fawziya A. R. Ibrahim, Fayed Attia Koutb Megahed, et al.
Biochemical Genetics (2024) Vol. 62, Iss. 6, pp. 5051-5072
Open Access | Times Cited: 3
Insights into spinal muscular atrophy from molecular biomarkers
Xiaodong Xing, Xinzhu Liu, Xiandeng Li, et al.
Neural Regeneration Research (2024) Vol. 20, Iss. 7, pp. 1849-1863
Open Access | Times Cited: 3
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy
Valeria Valsecchi, Francesco Errico, Valentina Bassareo, et al.
Communications Biology (2023) Vol. 6, Iss. 1
Open Access | Times Cited: 8
Association among biomarkers, phenotypes, and motor milestones in Chinese patients with 5q spinal muscular atrophy types 1–3
Shijia Ouyang, Xiaoyin Peng, Wen‐Chen Huang, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 2
Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1–3 patients treated with nusinersen
Goran Šimić, Vana Vukić, Marija Babić, et al.
CNS Neuroscience & Therapeutics (2022) Vol. 30, Iss. 3
Open Access | Times Cited: 11
Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen
Selena Trifunov, Daniel Natera‐de Benito, Laura Carrera‐García, et al.
Journal of Neuromuscular Diseases (2023) Vol. 10, Iss. 4, pp. 653-665
Open Access | Times Cited: 6
Spinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiation
Suzy Varderidou‐Minasian, Bert M. Verheijen, Oliver Harschnitz, et al.
ACS Omega (2021) Vol. 6, Iss. 51, pp. 35375-35388
Open Access | Times Cited: 14
Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
Rotem Orbach, Liora Sagi, Efraim Sadot, et al.
Muscle & Nerve (2022) Vol. 66, Iss. 6, pp. 762-766
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top